These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 16225485)

  • 1. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease.
    Bastida G; Nos P; Aguas M; Beltrán B; Rubín A; Dasí F; Ponce J
    Aliment Pharmacol Ther; 2005 Nov; 22(9):775-82. PubMed ID: 16225485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A histopathologic pattern of centrilobular hepatocyte injury suggests 6-mercaptopurine-induced hepatotoxicity in patients with inflammatory bowel disease.
    Masia R; Pratt DS; Misdraji J
    Arch Pathol Lab Med; 2012 Jun; 136(6):618-22. PubMed ID: 22646267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment.
    van Asseldonk DP; Seinen ML; de Boer NK; van Bodegraven AA; Mulder CJ
    J Crohns Colitis; 2012 Feb; 6(1):95-101. PubMed ID: 22261533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.
    Jharap B; de Boer NK; Stokkers P; Hommes DW; Oldenburg B; Dijkstra G; van der Woude CJ; de Jong DJ; Mulder CJ; van Elburg RM; van Bodegraven AA;
    Gut; 2014 Mar; 63(3):451-7. PubMed ID: 23424097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.
    Wong DR; Coenen MJ; Derijks LJ; Vermeulen SH; van Marrewijk CJ; Klungel OH; Scheffer H; Franke B; Guchelaar HJ; de Jong DJ; Engels LG; Verbeek AL; Hooymans PM;
    Aliment Pharmacol Ther; 2017 Feb; 45(3):391-402. PubMed ID: 27943397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients.
    Gisbert JP; Luna M; González-Lama Y; Pousa ID; Velasco M; Moreno-Otero R; Maté J
    Inflamm Bowel Dis; 2007 Sep; 13(9):1106-14. PubMed ID: 17455203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients.
    Shaye OA; Yadegari M; Abreu MT; Poordad F; Simon K; Martin P; Papadakis KA; Ippoliti A; Vasiliauskas E; Tran TT
    Am J Gastroenterol; 2007 Nov; 102(11):2488-94. PubMed ID: 17764490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease.
    Kreijne JE; Seinen ML; Wilhelm AJ; Bouma G; Mulder CJ; van Bodegraven AA; de Boer NK
    Ther Drug Monit; 2015 Dec; 37(6):797-804. PubMed ID: 25853923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TPMT genotype and the use of thiopurines in paediatric inflammatory bowel disease.
    Stocco G; Martelossi S; Barabino A; Fontana M; Lionetti P; Decorti G; Malusà N; Bartoli F; Fezzi M; Giraldi T; Ventura A
    Dig Liver Dis; 2005 Dec; 37(12):940-5. PubMed ID: 16202677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azathioprine and 6-Mercaptopurine-induced Liver Injury: Clinical Features and Outcomes.
    Björnsson ES; Gu J; Kleiner DE; Chalasani N; Hayashi PH; Hoofnagle JH;
    J Clin Gastroenterol; 2017 Jan; 51(1):63-69. PubMed ID: 27648552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease.
    López-Martín C; Chaparro M; Espinosa L; Bejerano A; Maté J; Gisbert JP
    Gastroenterol Hepatol; 2011; 34(6):385-92. PubMed ID: 21616565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
    Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H
    Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients.
    González-Lama Y; Bermejo F; López-Sanromán A; García-Sánchez V; Esteve M; Cabriada JL; McNicholl AG; Pajares R; Casellas F; Merino O; Carpio D; Vera MI; Muñoz C; Calvo M; Benito LM; Bujanda L; García-Fernández FJ; Ricart E; Ginard D; Velasco M; Carneros JA; Manceñido N; Calvo M; Algaba A; Froilan C; Cara C; Maté J; Abreu L; Gisbert JP;
    Aliment Pharmacol Ther; 2011 Sep; 34(5):544-54. PubMed ID: 21722149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver steatosis is a risk factor for hepatotoxicity in patients with inflammatory bowel disease under immunosuppressive treatment.
    Schröder T; Schmidt KJ; Olsen V; Möller S; Mackenroth T; Sina C; Lehnert H; Fellermann K; Büning J
    Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):698-704. PubMed ID: 25923946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease.
    Daperno M; Sostegni R; Canaparo R; Serpe L; Lavagna A; Crocellà L; Castagno F; Vernetto A; Rigazio C; Ercole E; D'Antico S; Pera A; Zara G; Rocca R
    Aliment Pharmacol Ther; 2009 Oct; 30(8):843-53. PubMed ID: 19650826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
    Kotlyar DS; Lewis JD; Beaugerie L; Tierney A; Brensinger CM; Gisbert JP; Loftus EV; Peyrin-Biroulet L; Blonski WC; Van Domselaar M; Chaparro M; Sandilya S; Bewtra M; Beigel F; Biancone L; Lichtenstein GR
    Clin Gastroenterol Hepatol; 2015 May; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
    Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
    Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease.
    Gearry RB; Barclay ML; Burt MJ; Collett JA; Chapman BA
    Pharmacoepidemiol Drug Saf; 2004 Aug; 13(8):563-7. PubMed ID: 15317038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol.
    Leong RW; Gearry RB; Sparrow MP
    Expert Opin Drug Saf; 2008 Sep; 7(5):607-16. PubMed ID: 18759713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease.
    Vasudevan A; Beswick L; Friedman AB; Moltzen A; Haridy J; Raghunath A; Sparrow M; van Langenberg D
    Dig Liver Dis; 2018 Jul; 50(7):682-688. PubMed ID: 29525182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.